A Novel 89zr-Anti-Pd-1 Immuno-Pet-Ct Improves Response Assessment To Immunotherapy In Lung Cancer

Immune checkpoint inhibitors (ICIs) significantly improve non-small cell lung cancer (NSCLC) patient survival. Response assessment of patients on ICIs represents a challenge since an increase in tumor size or the appearance of new lesions might reflect pseudoprogression (PP). PP has been reported in a range of 3-6% in NSCLC. Conventional 18F-FDG-PET scans do not accurately discriminate PP. We have recently reported the efficacy of a combined blockade of PD-1 and Id1 in a lung cancer mouse model (Baraibar et al.